Aleksas Matvekas

470 citations
7 papers · 307 indexed · h-index 6
Topics
Protein Degradation and Inhibitors (4 papers)Peptidase Inhibition and Analysis (3 papers)Ubiquitin and proteasome pathways (3 papers)
Partner nations
United States

In The Last Decade

Aleksas Matvekas

7 papers receiving 303 citations

Peers

Aleksas Matvekas
Comparison fields: 5 of 47
  • Molecular Biology 264
  • Oncology 102
  • Hematology 71
  • Pulmonary and Respiratory Medicine 46
  • Genetics 18
Replace Joshua M. Eichhorn with:
Joshua M. Eichhorn United States
Elena Ceccacci Italy
Matthew D. Witkin United States
L. Nolan United Kingdom
Gary Simmons United States
Yuanming He China
Rachael Brake United States
Yukie Harada Japan
Emanuela Ferrari Italy
Debra C. Ferguson United States
Aleksas Matvekas relative to Joshua M. Eichhorn United States Joshua M. Eichhorn's profile →
Citations per field
00.5×4.8×
Joshua M. Eichhorn · 1×
Citations per year

Countries citing papers authored by Aleksas Matvekas

Since Specialization
Citations

This map shows the geographic impact of Aleksas Matvekas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleksas Matvekas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleksas Matvekas more than expected).

Fields of papers citing papers by Aleksas Matvekas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleksas Matvekas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleksas Matvekas. The network helps show where Aleksas Matvekas may publish in the future.

Co-authorship network of co-authors of Aleksas Matvekas

This figure shows the co-authorship network connecting the top 25 collaborators of Aleksas Matvekas. A scholar is included among the top collaborators of Aleksas Matvekas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleksas Matvekas. Aleksas Matvekas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
#WorkIndexed citations
1 15
2 2
3 104
4 110
5 21
6 11
7 44

About Aleksas Matvekas

Aleksas Matvekas is a scholar working on Clinical Biochemistry, Nephrology and Pharmacology, having authored 7 papers that have together received 307 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (4 papers), Peptidase Inhibition and Analysis (3 papers) and Ubiquitin and proteasome pathways (3 papers). The work is most often cited by research in Hematology (71 citations), Molecular Biology (264 citations) and Oncology (102 citations). Aleksas Matvekas has collaborated with scholars based in United States. Frequent co-authors include Duxin Sun, Bo Wen, Donna McEachern, Shaomeng Wang, Hoda Metwally, Lijie Zhao, Lu Wang, Xin Han, Weiguo Xiang and Bukeyan Miao. Their work appears in journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026